gemeprost

Subscribe to Selected New Research on gemeprost

84 relevant articles (7 outcomes, 8 trials/studies) found for this Bio-Agent

Description: used for preoperative dilation of cervix before surgical abortion; RN given refers to (2E,11alpha,13E,15R)-isomer

Also Known As:

16,16-DMTDPGEME; 16,16-dimethyl-delta(2)-PGE1 methyl ester; 16,16-dimethyl-delta(2)-prostaglandin E1 methyl ester; 16,16-dimethyl-trans-delta(2)-PGE(1) methyl ester; 16,16-dimethyl-trans-delta(2)-prostaglandin E(1) methyl ester; Aventis brand of gemeprost; Cergem; Cervagem; Cervagème; Nourypharm brand of gemeprost; ONO 802; ONO-802; PG802; gemeprost, (2E,11alpha,13E,15R)-isomer; (2E,11 alpha,13E,15R)-11,15-dihydroxy-16,16- dimethyl-9-oxoprosta-2,13-dien-1-oic acid, methyl ester

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13315

Fatty Acids: 4660

Unsaturated Fatty Acids: 2221

Eicosanoids: 1153

Prostaglandins: 6157

Prostaglandins E: 1681

Alprostadil: 2477

gemeprost: 84

Monounsaturated Fatty Acids: 150

Alprostadil: 2477

gemeprost: 84

Biological Factors: 868

Inflammation Mediators: 485

Autacoids: 103

Eicosanoids: 1153

Prostaglandins: 6157

Prostaglandins E: 1681

Alprostadil: 2477

gemeprost: 84

Experts

1.	Lee, Eng Kiang: 1 article (12/2007)
2.	Yoshimura, Shu-Ichiro: 1 article (03/2007)
3.	Masuzaki, Hideaki: 1 article (03/2007)
4.	Miura, Kiyonori: 1 article (03/2007)
5.	Hiraki, Koichi: 1 article (03/2007)
6.	Nakayama, Daisuke: 1 article (03/2007)
7.	Ishimaru, Tadayuki: 1 article (03/2007)
8.	Vimercati, Antonella: 1 article (03/2005)
9.	Santamato, Sabino: 1 article (03/2005)
10.	Scioscia, Marco: 1 article (03/2005)

Related Diseases

1.	Amenorrhea 10/01/1989 - "2 recent studies have demonstrated that a regimen of a single oral dose of 600 mg of mifepristone (RU-486) followed 48 hours later by a 1 mg gemeprost pessary will induce complete abortion in over 95% of women with amenorrhea of less than 56 days' duration" 10/01/1991 - "90 primigravid women with 63-91 days of amenorrhea and ultrasonically confirmed single living fetus of correct size for gestational age were included; women were allocated to receive 200 mg mifepristone orally or an identical oral placebo 36 hours before their operation of 1 mg gemeprost vaginal pessary 3-4 hours preoperatively" 12/14/1990 - "In a British multicenter study, the combination of RU-486 and intravaginal gemeprost induced abortion in 95% of 600 women with up to 63 days of amenorrhea" 05/01/1989 - "To test the efficacy and side effects of these drugs when used in combination, 120 women of less than 56 days amenorrhea received a single 600 mg dose of mifepristone and 48 hours later 1/2 or 1 mg of the prostaglandin gemeprost administered in vaginal pessary form" 12/14/1990 - "In a multicenter study carried out in France, 1 600-mg dose of RU-486, followed 36-48 hours later by intramuscular sulprostone or intravaginal gemeprost, induced complete abortion in 96% of 2000 women with up to 49 days of amenorrhea" Get all the results and reference details, order at left...
2.	Spontaneous Abortion (Miscarriage) 08/01/1994 - "The purpose of this study was to determine the efficacy of a medical approach to the management of spontaneous abortion using the prostaglandin analogue, gemeprost" 09/01/1995 - "DESIGN: Retrospective comparison of histological features in fetuses aborted following maternal administration of gemeprost, with those in fetuses after spontaneous miscarriage" 04/09/2001 - "METHODS: A prospective, randomised study was carried out to clarify the effect of vaginal administration of a prostaglandin E1 analogue (gemeprost) versus surgical management (curettage) of miscarriages at up to twelve weeks of gestation" 01/01/2006 - "There was no statistically significant difference between vaginal misoprostol and gemeprost in the induction of miscarriage for fetal death after 13 weeks" 04/09/2001 - "DISCUSSIONS: Conservative treatment can substitute general anesthesia and curettage in the management of complete spontaneous abortions with fresh vaginal bleeding and an endometrial thickness of up to 10 mm. Vaginal administration of 1 mg gemeprost can substitute general anesthesia and curettage in the management of incomplete spontaneous abortions of up to 12 weeks of gestation and absence of a gestation sac." Get all the results and reference details, order at left...
3.	Missed Abortion 01/01/1987 - "Gemeprost was most effective in the missed abortion group (8/10 cases of complete abortion compared to 4/10 cases of complete abortion in the normal pregnancies)" 01/01/1987 - "It is concluded that gemeprost used after laminaria is convenient, safe, and effective for the termination of 2nd-trimester pregnancy especially in cases of missed abortion." 01/01/1995 - "Gemeprost for first trimester missed abortion." 01/01/1987 - "This study examined the efficacy of gemeprost in 2nd-trimester missed abortion (10 women) and in normal pregnancies selected for legal abortion (10 women)" 01/01/1987 - "Second trimester abortion using laminaria tents followed by 16, 16-dimethyl-trans-delta2-prostaglandin E1 methyl ester gemeprost for missed abortion and for legal abortion." Get all the results and reference details, order at left...
4.	Incomplete Abortion 05/31/1999 - "Four of 100 women were evacuated: one due to severe vaginal bleeding four hours after application of gemeprost, two because of womiting soon after having taken RU486 and one due to incomplete abortion" 06/01/1995 - "This study confirms the efficacy of the lower dose of mifepristone and further indicates the feasibility of a reduction in the gemeprost dose from the standard 1 mg to 0.5 mg. To reduce the rate of incomplete abortion associated with this procedure, it is recommended that misoprostol not be used in women with 49 or more days of amenorrhea." Get all the results and reference details, order at left...
5.	Abdominal Pain (Pain, Abdominal) 02/01/1995 - "Most women reported lower abdominal pain during the first few hours after gemeprost administration but few, if any, other side-effects were observed" 01/01/1991 - "Preoperative abdominal pain and gastrointestinal side-effects were significantly more frequent in the Cervagem group" 05/01/1992 - "On the first day, they inserted 4 vaginal pessaries of 1 mg gemeprost and administered 25-30 mg bupivacain through an epidural catheter to control abdominal pain" 01/01/1991 - "For Gemeprost patients, they were abdominal pain (55.5%) and headache (44.4%)" 03/01/1987 - "Side-effects were recorded in 33 (39%) cases in the sulprostone group and in 21 (23%) cases in the gemeprost group; in both groups, abdominal pain was the most common such symptom" Get all the results and reference details, order at left...
42 Diseases and 84 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Misoprostol (Cytotec)
2.	Mifepristone (RU 486)
3.	gemeprost
4.	Analgesics (Analgesic Drugs)
5.	Alprostadil (Muse)
6.	Suppositories (Vaginal Suppositories)
7.	sulprostone
8.	Dinoprost
9.	Dinoprostone (PGE2)
10.	isosorbide-5-mononitrate (Ismo)
24 Drugs and Important Bio-Agents and 53 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Pessaries
2.	Legal Abortion (Legal Abortions)
3.	Curettage
4.	Induced Abortion (Induced Abortions)
5.	Antibiotic Prophylaxis
9 Therapies and Procedures and 25 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>